Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration...

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Age-related macular degeneration (AMD) is a primary cause of vision impairment.
• Progression to geographic atrophy (GA) is a major challenge in AMD management.
• The role of dopaminergic therapies (DMTs) in AMD progression is not well understood.

Purpose of the Study:

• To investigate if dopaminergic therapies (DMTs) decrease the risk of AMD progressing to geographic atrophy (GA).
• To evaluate the potential protective effect of DMTs in patients with early or intermediate nonexudative AMD.

Main Methods:

• Retrospective cohort study of 320 patients (449 eyes) with early/intermediate nonexudative AMD.
• Comparison between 80 patients on DMTs and 240 control patients over a 10-year period (2014-2024).
• Annual evaluation of geographic atrophy (GA) progression over 5 years.

Main Results:

• Geographic atrophy (GA) progression was significantly lower in the DMT group (2.7%) compared to the non-DMT group (9.4%).
• Multivariate analysis confirmed a significant protective effect of DMTs (odds ratio 0.08, P < 0.001).
• DMTs demonstrated a statistically significant reduction in the rate of GA progression.

Conclusions:

• Dopaminergic therapies (DMTs) may offer a significant protective effect against the progression of age-related macular degeneration (AMD) to geographic atrophy (GA).
• These findings suggest DMTs as a potential therapeutic strategy for managing AMD progression.
• Further research is warranted to confirm these results and elucidate the underlying mechanisms.